Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ovarian cancer.

M V Seiden1

  • 1Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. Mseiden@partners.org

The Oncologist
|August 29, 2001
PubMed
Summary
This summary is machine-generated.

All women with invasive ovarian cancer should receive carboplatin-containing chemotherapy. For advanced disease, carboplatin with paclitaxel is standard, while carboplatin with docetaxel is a potential alternative. Novel agents are needed for platinum-resistant cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.

Gynecologic oncology·2006
Same author

Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.

Gynecologic oncology·2006
Same author

Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.

Gynecologic oncology·2006
Same author

A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same journal

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.

The oncologist·2026
Same journal

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

The oncologist·2026
See all related articles

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Clinical Trials

Background:

  • Ovarian cancer is a leading cause of death among gynecologic malignancies in the US.
  • Current treatment strategies are evolving based on recent clinical findings.

Purpose of the Study:

  • To summarize current recommendations for chemotherapy in early and advanced stage ovarian cancer.
  • To highlight challenges and potential future directions in treating platinum-resistant ovarian cancer.

Main Methods:

  • Review of studies presented at the American Society of Clinical Oncology.
  • Analysis of data on chemotherapy regimens for different stages of ovarian cancer.

Main Results:

  • Chemotherapy containing carboplatin is recommended for nearly all women with invasive ovarian cancer.

Related Experiment Videos

  • Carboplatin and paclitaxel are supported for newly diagnosed advanced disease; carboplatin and docetaxel show promise as an alternative.
  • Platinum-resistant ovarian cancer necessitates further investigation of novel agents.

    • Conclusions:

    • Carboplatin-based chemotherapy is a cornerstone in ovarian cancer treatment across stages.
    • Emerging therapies targeting growth factor receptors and novel drug classes require further evaluation for platinum-resistant disease.